Vimarsana
Biggest News Aggregation in the World

Craig Devoe News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Craig Devoe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Craig Devoe Today - Breaking & Trending Today

Alan Kaufman tells his story at Zuckerberg Cancer Center's Cancer Survivors Day - Vimarsana News

Alan Kaufman tells his story at Zuckerberg Cancer Center's Cancer Survivors Day

"I get up every morning, and I say it out loud: 'Every new day is a gift,' " said Alan Kaufman, 66, of Forest Hills, who has been in remissions since 2020.

Why Melanoma May Need Treatment After Surgery - Vimarsana News

Why Melanoma May Need Treatment After Surgery

An expert discusses why patients with melanoma may undergo treatment even after their tumor was surgically removed, and how melanoma became the “poster child” for immunotherapy.

Post-Surgical Opdivo 'Just Makes Sense' for Stage 2B, 2C Melanoma - Vimarsana News

Post-Surgical Opdivo 'Just Makes Sense' for Stage 2B, 2C Melanoma

An expert reflects on the recent FDA approval of adjuvant Opdivo for patients with stage 2B or 2C melanoma.

Neoadjuvant pembrolizumab achieves major pathologic response in more than half of patients with resectable melanoma - Vimarsana News

Neoadjuvant pembrolizumab achieves major pathologic response in more than half of patients with resectable melanoma

In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab.

Major pathologic response to neoadjuvant pemb - Vimarsana News

Major pathologic response to neoadjuvant pemb

<p style="text-align:start">In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab.&nbsp;These and other results of the analyses are presented as a proffered paper (Abstract LBA48) at the European Society of Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on Monday, October 23, by Sapna P. Patel, MD, chair of the SWOG melanoma committee and ...